Emerging drugs for amyotrophic lateral sclerosis

Bibliography

• Traynor BJ, Codd MB, Corr B, Incidence and prevalence of ALS in Ireland, 1995 – 1997: a population-based study. Neurology 1999;16(3):504-9
   Google Scholar
• Vazquez MC, Ketzoian C, Legnani C, Incidence and prevalence of amyotrophic lateral sclerosis in Uruguay: a population-based study. Neuroepidemiology 2008;30(2):105-11
   PubMed Web of Science ®Google Scholar
• Chio A, Mora G, Calvo A, Epidemiology of ALS in Italy: a 10-year prospective population-based study. Neurology 2009;72(8):725-31
   PubMed Web of Science ®Google Scholar
• Brooks BR. El Escorial world federation of neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on motor neuron diseases/amyotrophic lateral sclerosis of the world federation of neurology research group on neuromuscular diseases and the El Escorial “Clinical limits of amyotrophic lateral sclerosis” workshop contributors. J Neurol Sci 1994;124(Suppl):96-107
   PubMed Web of Science ®Google Scholar
• Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1(5):293-9
   PubMed Web of Science ®Google Scholar
• de Carvalho M, Dengler R, Eisen A, Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol 2008;119(3):497-503
   PubMed Web of Science ®Google Scholar
• Fang F, Valdimarsdottir U, Bellocco R, Amyotrophic lateral sclerosis in Sweden, 1991-2005. Arch Neurol 2009;66(4):515-19
   PubMed Web of Science ®Google Scholar
• del Aguila MA, Longstreth WT Jr, McGuire V, Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology 2003;60(5):813-19
   PubMed Web of Science ®Google Scholar
• Zoccolella S, Beghi E, Palagano G, Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry 2008;79(1):33-7
   PubMed Web of Science ®Google Scholar
• Chio A, Mora G, Leone M, Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology 2002;59(1):99-103
   PubMed Web of Science ®Google Scholar
• Dupuis L, Pradat PF, Ludolph AC, Loeffler JP. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol 2011;10(1):75-82
   PubMed Web of Science ®Google Scholar
• Jawaid A, Murthy SB, Wilson AM, A decrease in body mass index is associated with faster progression of motor symptoms and shorter survival in ALS. Amyotroph Lateral Scler 2010;11(6):542-8
   PubMed Web of Science ®Google Scholar
• Chio A, Logroscino G, Hardiman O, Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler 2009;10(5-6):310-23
   PubMed Web of Science ®Google Scholar
• Miller RG, Anderson F, Brooks BR, Outcomes research in amyotrophic lateral sclerosis: lessons learned from the amyotrophic lateral sclerosis clinical assessment, research, and education database. Ann Neurol 2009;65(Suppl 1):S24-8
   PubMed Web of Science ®Google Scholar
• Sobue G. Current status of patients with ALS in Japan: based on the data from patients' personal reports in specific diseases. The Annual Report 2005 of the Research Committee of the Neurodegenerative Diseases of the Ministry of Health, Labour and Welfare. Chair: Shigeki Kuzuhara, MD, in Japanese; 2005
   Google Scholar
• Strong MJ. The syndromes of frontotemporal dysfunction in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2008;9(6):323-38
   PubMed Web of Science ®Google Scholar
• Traynor BJ, Codd MB, Corr B, Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: a population-based study. Arch Neurol 2000;57(8):1171-6
   PubMed Web of Science ®Google Scholar
• Sorenson EJ, Stalker AP, Kurland LT, Windebank AJ. Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998. Neurology 2002;59(2):280-2
   PubMed Web of Science ®Google Scholar
• Rosen DR. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;364(6435):362
   PubMed Web of Science ®Google Scholar
• Valdmanis PN, Daoud H, Dion PA, Rouleau GA. Recent advances in the genetics of amyotrophic lateral sclerosis. Curr Neurol Neurosci Rep 2009;9(3):198-205
   PubMed Web of Science ®Google Scholar
• Maruyama H, Morino H, Ito H, Mutations of optineurin in amyotrophic lateral sclerosis. Nature 2010;465(7295):223-6
   PubMed Web of Science ®Google Scholar
• Mitchell J, Paul P, Chen HJ, Familial amyotrophic lateral sclerosis is associated with a mutation in D-amino acid oxidase. Proc Natl Acad Sci USA 2010;107(16):7556-61
   PubMed Web of Science ®Google Scholar
• Johnson JO, Mandrioli J, Benatar M, Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 2010;68(5):857-64
   PubMed Web of Science ®Google Scholar
• Siddique N, Siddique T. Genetics of amyotrophic lateral sclerosis. Phys Med Rehabil Clin N Am 2008;19(3):429-39; vii
   PubMed Web of Science ®Google Scholar
• Mitsumoto H, Przedborski S, Gordon PH. Amyotrophic lateral sclerosis. Taylor & Francis; New York: 2006
   Google Scholar
• Laaksovirta H, Peuralinna T, Schymick JC, Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study. Lancet Neurol 2010;9(10):978-85
   PubMed Web of Science ®Google Scholar
• Haley RW. Excess incidence of ALS in young Gulf War veterans. Neurology 2003;61(6):750-6
   PubMed Web of Science ®Google Scholar
• Horner RD, Kamins KG, Feussner JR, Occurrence of amyotrophic lateral sclerosis among Gulf War veterans. Neurology 2003;61(6):742-9
   PubMed Web of Science ®Google Scholar
• Weisskopf MG, O'Reilly EJ, McCullough ML, Prospective study of military service and mortality from ALS. Neurology 2005;64(1):32-7
   PubMed Web of Science ®Google Scholar
• Barth SK, Kang HK, Bullman TA, Wallin MT. Neurological mortality among U.S. veterans of the Persian Gulf War: 13-year follow-up. Am J Ind Med 2009;52(9):663-70
   PubMed Web of Science ®Google Scholar
• Chio A, Benzi G, Dossena M, Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Brain 2005;128(Pt 3):472-6
   PubMedGoogle Scholar
• Chio A, Calvo A, Dossena M, ALS in Italian professional soccer players: the risk is still present and could be soccer-specific. Amyotroph Lateral Scler 2009;10(4):205-9
   PubMed Web of Science ®Google Scholar
• Dupuis L, Corcia P, Fergani A, Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 2008;70(13):1004-9
   PubMed Web of Science ®Google Scholar
• Dorst J, Kuhnlein P, Hendrich C, Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol 2011;258(4):613-17
   PubMed Web of Science ®Google Scholar
• Chio A, Calvo A, Ilardi A, Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology 2009;73(20):1681-5
   PubMed Web of Science ®Google Scholar
• Jawaid A, Salamone AR, Strutt AM, ALS disease onset may occur later in patients with pre-morbid diabetes mellitus. Eur J Neurol 2010;17(5):733-9
   PubMed Web of Science ®Google Scholar
• Dupuis L, Oudart H, Rene F, Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proc Natl Acad Sci USA 2004;101(30):11159-64
   PubMed Web of Science ®Google Scholar
• Edwards IR, Star K, Kiuru A. Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase. Drug Saf 2007;30(6):515-25
   PubMed Web of Science ®Google Scholar
• Golomb BA, Kwon EK, Koperski S, Evans MA. Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study. Drug Saf 2009;32(8):649-61
   PubMed Web of Science ®Google Scholar
• Colman E, Szarfman A, Wyeth J, An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system. Pharmacoepidemiol Drug Saf 2008;17(11):1068-76
   PubMed Web of Science ®Google Scholar
• Sorensen HT, Riis AH, Lash TL, Pedersen L. Statin use and risk of amyotrophic lateral sclerosis and other motor neuron disorders. Circ Cardiovasc Qual Outcomes 3(4):413-17
   PubMed Web of Science ®Google Scholar
• Zinman L, Sadeghi R, Gawel M, Are statin medications safe in patients with ALS? Amyotroph Lateral Scler 2008;9(4):223-8
   PubMed Web of Science ®Google Scholar
• Drory VE, Bronipolsky T, Artamonov I, Nefussy B. Influence of statins treatment on survival in patients with amyotrophic lateral sclerosis. J Neurol Sci 2008;273(1-2):81-3
   PubMed Web of Science ®Google Scholar
• Schymick JC, Talbot K, Traynor BJ. Genetics of sporadic amyotrophic lateral sclerosis. Hum Mol Genet 2007;16(Spec No. 2):R233-42
   PubMedGoogle Scholar
• Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol 2009;65(Suppl 1):S3-9
   PubMed Web of Science ®Google Scholar
• McElhiney MC, Rabkin JG, Gordon PH, Prevalence of fatigue and depression in ALS patients and change over time. J Neurol Neurosurg Psychiatry 2009;80(10):1146-9
   PubMed Web of Science ®Google Scholar
• Rabkin JG, Albert SM, Del Bene ML, Prevalence of depressive disorders and change over time in late-stage ALS. Neurology 2005;65(1):62-7
   PubMed Web of Science ®Google Scholar
• Chio A, Gauthier A, Vignola A, Caregiver time use in ALS. Neurology 2006;67(5):902-4
   PubMed Web of Science ®Google Scholar
• Gauthier A, Vignola A, Calvo A, A longitudinal study on quality of life and depression in ALS patient-caregiver couples. Neurology 2007;68(12):923-6
   PubMed Web of Science ®Google Scholar
• Klein LM, Forshew DA. The economic impact of ALS. Neurology 1996;47(4 Suppl 2):S126-9
   PubMed Web of Science ®Google Scholar
• Lopez-Bastida J, Perestelo-Perez L, Monton-Alvarez F, Social economic costs and health-related quality of life in patients with amyotrophic lateral sclerosis in Spain. Amyotroph Lateral Scler 2009;10(4):237-43
   PubMed Web of Science ®Google Scholar
• Elman LB, Stanley L, Gibbons P, McCluskey L. A cost comparison of hospice care in amyotrophic lateral sclerosis and lung cancer. Am J Hosp Palliat Care 2006;23(3):212-16
   PubMedGoogle Scholar
• Chio A, Bottacchi E, Buffa C, Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. J Neurol Neurosurg Psychiatry 2006;77(8):948-50
   PubMed Web of Science ®Google Scholar
• van der Steen I, van den Berg JP, Buskens E, The costs of amyotrophic lateral sclerosis, according to type of care. Amyotroph Lateral Scler 2009;10(1):27-34
   PubMed Web of Science ®Google Scholar
• Miller RG, Jackson CE, Kasarskis EJ, Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73(15):1227-33
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994;330(9):585-91
   PubMed Web of Science ®Google Scholar
• Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2007(1):CD001447
   PubMed Web of Science ®Google Scholar
• Miller RG, Jackson CE, Kasarskis EJ, Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73(15):1218-26
   PubMed Web of Science ®Google Scholar
• Logroscino G, Traynor BJ, Hardiman O, Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry 2010;81(4):385-90
   PubMed Web of Science ®Google Scholar
• Mitsumoto J, Dorsey ER, Beck CA, Pivotal studies of orphan drugs approved for neurological diseases. Ann Neurol 2009;66(2):184-90
   PubMed Web of Science ®Google Scholar
• Buckley BM. Clinical trials of orphan medicines. Lancet 2008;371(9629):2051-5
   PubMed Web of Science ®Google Scholar
• Wong PC, Pardo CA, Borchelt DR, An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995;14(6):1105-16
   PubMed Web of Science ®Google Scholar
• Bruijn LI, Becher MW, Lee MK, ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 1997;18(2):327-38
   PubMed Web of Science ®Google Scholar
• Bruijn LI, Houseweart MK, Kato S, Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 1998;281(5384):1851-4
   PubMed Web of Science ®Google Scholar
• Jaarsma D, Haasdijk ED, Grashorn JA, Human Cu/Zn superoxide dismutase (SOD1) overexpression in mice causes mitochondrial vacuolization, axonal degeneration, and premature motoneuron death and accelerates motoneuron disease in mice expressing a familial amyotrophic lateral sclerosis mutant SOD1. Neurobiol Dis 2000;7(6 Pt B):623-43
   PubMed Web of Science ®Google Scholar
• Wang L, Deng HX, Grisotti G, Wild-type SOD1 overexpression accelerates disease onset of a G85R SOD1 mouse. Hum Mol Genet 2009;18(9):1642-51
   PubMed Web of Science ®Google Scholar
• Boillee S, Yamanaka K, Lobsiger CS, Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006;312(5778):1389-92
   PubMed Web of Science ®Google Scholar
• Neumann M, Sampathu DM, Kwong LK, Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314(5796):130-3
   PubMed Web of Science ®Google Scholar
• Arai T, Hasegawa M, Akiyama H, TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2006;351(3):602-11
   PubMed Web of Science ®Google Scholar
• Mackenzie IR, Bigio EH, Ince PG, Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 2007;61(5):427-34
   PubMed Web of Science ®Google Scholar
• Robertson J, Sanelli T, Xiao S, Lack of TDP-43 abnormalities in mutant SOD1 transgenic mice shows disparity with ALS. Neurosci Lett 2007;420(2):128-32
   PubMed Web of Science ®Google Scholar
• Turner BJ, Baumer D, Parkinson NJ, TDP-43 expression in mouse models of amyotrophic lateral sclerosis and spinal muscular atrophy. BMC Neurosci 2008;9:104
   PubMed Web of Science ®Google Scholar
• Sreedharan J, Blair IP, Tripathi VB, TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008;319(5870):1668-72
   PubMed Web of Science ®Google Scholar
• Gitcho MA, Baloh RH, Chakraverty S, TDP-43 A315T mutation in familial motor neuron disease. Ann Neurol 2008;63(4):535-8
   PubMed Web of Science ®Google Scholar
• Kabashi E, Valdmanis PN, Dion P, TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet 2008;40(5):572-4
   PubMed Web of Science ®Google Scholar
• Van Deerlin VM, Leverenz JB, Bekris LM, TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol 2008;7(5):409-16
   PubMed Web of Science ®Google Scholar
• Lagier-Tourenne C, Cleveland DW. Rethinking ALS: the FUS about TDP-43. Cell 2009;136(6):1001-4
   PubMed Web of Science ®Google Scholar
• Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009;323(5918):1205-8
   PubMed Web of Science ®Google Scholar
• Vance C, Rogelj B, Hortobagyi T, Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009;323(5918):1208-11
   PubMed Web of Science ®Google Scholar
• Abalkhail H, Mitchell J, Habgood J, A new familial amyotrophic lateral sclerosis locus on chromosome 16q12.1-16q12.2. Am J Hum Genet 2003;73(2):383-9
   PubMed Web of Science ®Google Scholar
• Ruddy DM, Parton MJ, Al-Chalabi A, Two families with familial amyotrophic lateral sclerosis are linked to a novel locus on chromosome 16q. Am J Hum Genet 2003;73(2):390-6
   PubMed Web of Science ®Google Scholar
• Chio A, Restagno G, Brunetti M, Two Italian kindreds with familial amyotrophic lateral sclerosis due to FUS mutation. Neurobiol Aging 2009;30(8):1272-5
   PubMed Web of Science ®Google Scholar
• Ticozzi N, Silani V, LeClerc AL, Analysis of FUS gene mutation in familial amyotrophic lateral sclerosis within an Italian cohort. Neurology 2009;73(15):1180-5
   PubMed Web of Science ®Google Scholar
• Belzil VV, Valdmanis PN, Dion PA, Mutations in FUS cause FALS and SALS in French and French Canadian populations. Neurology 2009;73(15):1176-9
   PubMed Web of Science ®Google Scholar
• Damme PV, Goris A, Race V, The occurrence of mutations in FUS in a Belgian cohort of patients with familial ALS. Eur J Neurol 2010;17(5):754-6
   PubMed Web of Science ®Google Scholar
• Corrado L, Del Bo R, Castellotti B, Mutations of FUS gene in sporadic amyotrophic lateral sclerosis. J Med Genet 2010;47(3):190-4
   PubMed Web of Science ®Google Scholar
• Blair IP, Williams KL, Warraich ST, FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. J Neurol Neurosurg Psychiatry 2010;81(6):639-45
   PubMed Web of Science ®Google Scholar
• Groen EJ, van Es MA, van Vught PW, FUS mutations in familial amyotrophic lateral sclerosis in the Netherlands. Arch Neurol 2010;67(2):224-30
   PubMed Web of Science ®Google Scholar
• Baumer D, Hilton D, Paine SM, Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations. Neurology 2010;75(7):611-18
   PubMed Web of Science ®Google Scholar
• Strong MJ. The evidence for altered RNA metabolism in amyotrophic lateral sclerosis (ALS). J Neurol Sci 2010;288(1-2):1-12
   PubMed Web of Science ®Google Scholar
• Rothstein JD, Tsai G, Kuncl RW, Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990;28(1):18-25
   PubMed Web of Science ®Google Scholar
• Spreux-Varoquaux O, Bensimon G, Lacomblez L, Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J Neurol Sci 2002;193(2):73-8
   PubMed Web of Science ®Google Scholar
• Rothstein JD, Van Kammen M, Levey AI, Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995;38(1):73-84
   PubMed Web of Science ®Google Scholar
• Milton ID, Banner SJ, Ince PG, Expression of the glial glutamate transporter EAAT2 in the human CNS: an immunohistochemical study. Brain Res Mol Brain Res 1997;52(1):17-31
   PubMedGoogle Scholar
• Rothstein JD, Dykes-Hoberg M, Pardo CA, Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 1996;16(3):675-86
   PubMed Web of Science ®Google Scholar
• Howland DS, Liu J, She Y, Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci USA 2002;99(3):1604-9
   PubMed Web of Science ®Google Scholar
• Guo H, Lai L, Butchbach ME, Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice. Hum Mol Genet 2003;12(19):2519-32
   PubMed Web of Science ®Google Scholar
• Van Damme P, Dewil M, Robberecht W, Van Den Bosch L. Excitotoxicity and amyotrophic lateral sclerosis. Neurodegener Dis 2005;2(3-4):147-59
   PubMed Web of Science ®Google Scholar
• Van Damme P, Braeken D, Callewaert G, GluR2 deficiency accelerates motor neuron degeneration in a mouse model of amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2005;64(7):605-12
   PubMed Web of Science ®Google Scholar
• Tateno M, Sadakata H, Tanaka M, Calcium-permeable AMPA receptors promote misfolding of mutant SOD1 protein and development of amyotrophic lateral sclerosis in a transgenic mouse model. Hum Mol Genet 2004;13(19):2183-96
   PubMed Web of Science ®Google Scholar
• Van Damme P, Bogaert E, Dewil M, Astrocytes regulate GluR2 expression in motor neurons and their vulnerability to excitotoxicity. Proc Natl Acad Sci USA 2007;104(37):14825-30
   PubMed Web of Science ®Google Scholar
• Rothstein JD, Patel S, Regan MR, Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005;433(7021):73-7
   PubMed Web of Science ®Google Scholar
• Gurney ME, Cutting FB, Zhai P, Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996;39(2):147-57
   PubMed Web of Science ®Google Scholar
• Maragakis NJ, Jackson M, Ganel R, Rothstein JD. Topiramate protects against motor neuron degeneration in organotypic spinal cord cultures but not in G93A SOD1 transgenic mice. Neurosci Lett 2003;338(2):107-10
   PubMed Web of Science ®Google Scholar
• Miller RG, Moore D, Young LA, Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group. Neurology 1996;47(6):1383-8
   PubMed Web of Science ®Google Scholar
• Miller RG, Moore DH II, Gelinas DF, Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001;56(7):843-8
   PubMed Web of Science ®Google Scholar
• Eisen A, Stewart H, Schulzer M, Cameron D. Anti-glutamate therapy in amyotrophic lateral sclerosis: a trial using lamotrigine. Can J Neurol Sci 1993;20(4):297-301
   PubMed Web of Science ®Google Scholar
• Ryberg H, Askmark H, Persson LI. A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters. Acta Neurol Scand 2003;108(1):1-8
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Shefner JM, Schoenfeld DA, A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 2003;61(4):456-64
   PubMed Web of Science ®Google Scholar
• Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006;443(7113):787-95
   PubMed Web of Science ®Google Scholar
• Mattiazzi M, D'Aurelio M, Gajewski CD, Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J Biol Chem 2002;277(33):29626-33
   PubMed Web of Science ®Google Scholar
• Kirkinezos IG, Bacman SR, Hernandez D, Cytochrome c association with the inner mitochondrial membrane is impaired in the CNS of G93A-SOD1 mice. J Neurosci 2005;25(1):164-72
   PubMed Web of Science ®Google Scholar
• Bendotti C, Calvaresi N, Chiveri L, Early vacuolization and mitochondrial damage in motor neurons of FALS mice are not associated with apoptosis or with changes in cytochrome oxidase histochemical reactivity. J Neurol Sci 2001;191(1-2):25-33
   PubMed Web of Science ®Google Scholar
• Ahtoniemi T, Jaronen M, Keksa-Goldsteine V, Mutant SOD1 from spinal cord of G93A rats is destabilized and binds to inner mitochondrial membrane. Neurobiol Dis 2008;32(3):479-85
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Kobayashi Y, Ishigaki S, Mitochondrial localization of mutant superoxide dismutase 1 triggers caspase-dependent cell death in a cellular model of familial amyotrophic lateral sclerosis. J Biol Chem 2002;277(52):50966-72
   PubMed Web of Science ®Google Scholar
• Higgins CM, Jung C, Xu Z. ALS-associated mutant SOD1G93A causes mitochondrial vacuolation by expansion of the intermembrane space and by involvement of SOD1 aggregation and peroxisomes. BMC Neurosci 2003;4:16
   PubMed Web of Science ®Google Scholar
• Guegan C, Vila M, Rosoklija G, Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis. J Neurosci 2001;21(17):6569-76
   PubMed Web of Science ®Google Scholar
• Crugnola V, Lamperti C, Lucchini V, Mitochondrial respiratory chain dysfunction in muscle from patients with amyotrophic lateral sclerosis. Arch Neurol 2010;67(7):849-54
   PubMed Web of Science ®Google Scholar
• Klivenyi P, Ferrante RJ, Matthews RT, Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999;5(3):347-50
   PubMed Web of Science ®Google Scholar
• Zhu S, Stavrovskaya IG, Drozda M, Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002;417(6884):74-8
   PubMed Web of Science ®Google Scholar
• Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 2002;13(8):1067-70
   PubMed Web of Science ®Google Scholar
• Kriz J, Nguyen MD, Julien JP. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2002;10(3):268-78
   PubMed Web of Science ®Google Scholar
• Kirkinezos IG, Hernandez D, Bradley WG, Moraes CT. An ALS mouse model with a permeable blood-brain barrier benefits from systemic cyclosporine A treatment. J Neurochem 2004;88(4):821-6
   PubMed Web of Science ®Google Scholar
• Groeneveld GJ, Veldink JH, van der Tweel I, A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 2003;53(4):437-45
   PubMed Web of Science ®Google Scholar
• Shefner JM, Cudkowicz ME, Schoenfeld D, A clinical trial of creatine in ALS. Neurology 2004;63(9):1656-61
   PubMed Web of Science ®Google Scholar
• Gordon PH, Moore DH, Miller RG, Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007;6(12):1045-53
   PubMed Web of Science ®Google Scholar
• Barber SC, Mead RJ, Shaw PJ. Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target. Biochim Biophys Acta 2006;1762(11-12):1051-67
   PubMed Web of Science ®Google Scholar
• Bogdanov M, Brown RH, Matson W, Increased oxidative damage to DNA in ALS patients. Free Radic Biol Med 2000;29(7):652-8
   PubMed Web of Science ®Google Scholar
• Simpson EP, Henry YK, Henkel JS, Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden. Neurology 2004;62(10):1758-65
   PubMed Web of Science ®Google Scholar
• Mitsumoto H, Santella RM, Liu X, Oxidative stress biomarkers in sporadic ALS. Amyotroph Lateral Scler 2008;9(3):177-83
   PubMed Web of Science ®Google Scholar
• Murata T, Ohtsuka C, Terayama Y. Increased mitochondrial oxidative damage in patients with sporadic amyotrophic lateral sclerosis. J Neurol Sci 2008;267(1-2):66-9
   PubMed Web of Science ®Google Scholar
• Sohmiya M, Tanaka M, Suzuki Y, An increase of oxidized coenzyme Q-10 occurs in the plasma of sporadic ALS patients. J Neurol Sci 2005;228(1):49-53
   PubMed Web of Science ®Google Scholar
• Louwerse ES, Weverling GJ, Bossuyt PM, Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch Neurol 1995;52(6):559-64
   PubMed Web of Science ®Google Scholar
• Lange DJ, Murphy PL, Diamond B, Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. Arch Neurol 1998;55(1):93-6
   PubMed Web of Science ®Google Scholar
• Desnuelle C, Dib M, Garrel C, Favier A. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord 2001;2(1):9-18
   PubMed Web of Science ®Google Scholar
• Graf M, Ecker D, Horowski R, High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm 2005;112(5):649-60
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Thompson JL, Levy G, Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol 2009;66(2):235-44
   PubMed Web of Science ®Google Scholar
• Kanekura K, Suzuki H, Aiso S, Matsuoka M. ER stress and unfolded protein response in amyotrophic lateral sclerosis. Mol Neurobiol 2009;39(2):81-9
   PubMed Web of Science ®Google Scholar
• Tobisawa S, Hozumi Y, Arawaka S, Mutant SOD1 linked to familial amyotrophic lateral sclerosis, but not wild-type SOD1, induces ER stress in COS7 cells and transgenic mice. Biochem Biophys Res Commun 2003;303(2):496-503
   PubMed Web of Science ®Google Scholar
• Wootz H, Hansson I, Korhonen L, Lindholm D. XIAP decreases caspase-12 cleavage and calpain activity in spinal cord of ALS transgenic mice. Exp Cell Res 2006;312(10):1890-8
   PubMed Web of Science ®Google Scholar
• Atkin JD, Farg MA, Turner BJ, Induction of the unfolded protein response in familial amyotrophic lateral sclerosis and association of protein-disulfide isomerase with superoxide dismutase 1. J Biol Chem 2006;281(40):30152-65
   PubMed Web of Science ®Google Scholar
• Nishitoh H, Kadowaki H, Nagai A, ALS-linked mutant SOD1 induces ER stress- and ASK1-dependent motor neuron death by targeting Derlin-1. Genes Dev 2008;22(11):1451-64
   PubMed Web of Science ®Google Scholar
• Nishimura AL, Mitne-Neto M, Silva HC, A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet 2004;75(5):822-31
   PubMed Web of Science ®Google Scholar
• Ilieva EV, Ayala V, Jove M, Oxidative and endoplasmic reticulum stress interplay in sporadic amyotrophic lateral sclerosis. Brain 2007;130(Pt 12):3111-23
   PubMed Web of Science ®Google Scholar
• Oyanagi K, Yamazaki M, Takahashi H, Spinal anterior horn cells in sporadic amyotrophic lateral sclerosis show ribosomal detachment from, and cisternal distention of the rough endoplasmic reticulum. Neuropathol Appl Neurobiol 2008;34(6):650-8
   PubMed Web of Science ®Google Scholar
• Kakiuchi C, Ishigaki S, Oslowski CM, Valproate, a mood stabilizer, induces WFS1 expression and modulates its interaction with ER stress protein GRP94. PLoS One 2009;4(1):e4134
   PubMedGoogle Scholar
• Shao L, Sun X, Xu L, Mood stabilizing drug lithium increases expression of endoplasmic reticulum stress proteins in primary cultured rat cerebral cortical cells. Life Sci 2006;78(12):1317-23
   PubMed Web of Science ®Google Scholar
• Aggarwal SP, Zinman L, Simpson E, Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9(5):481-8
   PubMed Web of Science ®Google Scholar
• Chio A, Borghero G, Calvo A, Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial. Neurology 2010;75(7):619-25
   PubMed Web of Science ®Google Scholar
• Piepers S, Veldink JH, de Jong SW, Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. Ann Neurol 2009;66(2):227-34
   PubMed Web of Science ®Google Scholar
• Kamo H, Haebara H, Akiguchi I, A distinctive distribution of reactive astroglia in the precentral cortex in amyotrophic lateral sclerosis. Acta Neuropathol 1987;74(1):33-8
   PubMed Web of Science ®Google Scholar
• Troost D, Claessen N, van den Oord JJ, Neuronophagia in the motor cortex in amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol 1993;19(5):390-7
   PubMed Web of Science ®Google Scholar
• Moisse K, Strong MJ. Innate immunity in amyotrophic lateral sclerosis. Biochim Biophys Acta 2006;1762(11-12):1083-93
   PubMed Web of Science ®Google Scholar
• Pramatarova A, Laganiere J, Roussel J, Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J Neurosci 2001;21(10):3369-74
   PubMed Web of Science ®Google Scholar
• Gong YH, Parsadanian AS, Andreeva A, Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration. J Neurosci 2000;20(2):660-5
   PubMed Web of Science ®Google Scholar
• Clement AM, Nguyen MD, Roberts EA, Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 2003;302(5642):113-17
   PubMed Web of Science ®Google Scholar
• Nagai M, Re DB, Nagata T, Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci 2007;10(5):615-22
   PubMed Web of Science ®Google Scholar
• Di Giorgio FP, Carrasco MA, Siao MC, Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat Neurosci 2007;10(5):608-14
   PubMed Web of Science ®Google Scholar
• Baron P, Bussini S, Cardin V, Production of monocyte chemoattractant protein-1 in amyotrophic lateral sclerosis. Muscle Nerve 2005;32(4):541-4
   PubMed Web of Science ®Google Scholar
• Wilms H, Sievers J, Dengler R, Intrathecal synthesis of monocyte chemoattractant protein-1 (MCP-1) in amyotrophic lateral sclerosis: further evidence for microglial activation in neurodegeneration. J Neuroimmunol 2003;144(1-2):139-42
   PubMed Web of Science ®Google Scholar
• Nagata T, Nagano I, Shiote M, Elevation of MCP-1 and MCP-1/VEGF ratio in cerebrospinal fluid of amyotrophic lateral sclerosis patients. Neurol Res 2007;29(8):772-6
   PubMed Web of Science ®Google Scholar
• Turner MR, Cagnin A, Turkheimer FE, Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis 2004;15(3):601-9
   PubMed Web of Science ®Google Scholar
• Beers DR, Henkel JS, Xiao Q, Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2006;103(43):16021-6
   PubMed Web of Science ®Google Scholar
• Appel SH, Engelhardt JI, Henkel JS, Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. Neurology 2008;71(17):1326-34
   PubMed Web of Science ®Google Scholar
• Zhang W, Narayanan M, Friedlander RM. Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol 2003;53(2):267-70
   PubMed Web of Science ®Google Scholar
• Drachman DB, Frank K, Dykes-Hoberg M, Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol 2002;52(6):771-8
   PubMed Web of Science ®Google Scholar
• Klivenyi P, Kiaei M, Gardian G, Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem 2004;88(3):576-82
   PubMed Web of Science ®Google Scholar
• Kiaei M, Kipiani K, Petri S, Integrative role of cPLA with COX-2 and the effect of non-steriodal anti-inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem 2005;93(2):403-11
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Shefner JM, Schoenfeld DA, Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol 2006;60(1):22-31
   PubMed Web of Science ®Google Scholar
• Mitsumoto H, Gambetti P. Impaired slow axonal transport in wobbler mouse motor neuron disease. Ann Neurol 1986;19(1):36-43
   PubMed Web of Science ®Google Scholar
• Mitsumoto H, Ferut AL, Kurahashi K, McQuarrie IG. Impairment of retrograde axonal transport in wobbler mouse motor neuron disease. Muscle Nerve 1990;13(2):121-6
   PubMed Web of Science ®Google Scholar
• Mitsumoto H, Kurahashi K, Jacob JM, McQuarrie IG. Retardation of fast axonal transport in wobbler mice. Muscle Nerve 1993;16(5):542-7
   PubMed Web of Science ®Google Scholar
• Williamson TL, Cleveland DW. Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nat Neurosci 1999;2(1):50-6
   PubMed Web of Science ®Google Scholar
• Xu Z, Cork LC, Griffin JW, Cleveland DW. Increased expression of neurofilament subunit NF-L produces morphological alterations that resemble the pathology of human motor neuron disease. Cell 1993;73(1):23-33
   PubMed Web of Science ®Google Scholar
• Lee MK, Marszalek JR, Cleveland DW. A mutant neurofilament subunit causes massive, selective motor neuron death: implications for the pathogenesis of human motor neuron disease. Neuron 1994;13(4):975-88
   PubMed Web of Science ®Google Scholar
• Williamson TL, Bruijn LI, Zhu Q, Absence of neurofilaments reduces the selective vulnerability of motor neurons and slows disease caused by a familial amyotrophic lateral sclerosis-linked superoxide dismutase 1 mutant. Proc Natl Acad Sci USA 1998;95(16):9631-6
   PubMed Web of Science ®Google Scholar
• Couillard-Despres S, Zhu Q, Wong PC, Protective effect of neurofilament heavy gene overexpression in motor neuron disease induced by mutant superoxide dismutase. Proc Natl Acad Sci USA 1998;95(16):9626-30
   PubMed Web of Science ®Google Scholar
• Nguyen MD, Lariviere RC, Julien JP. Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions. Neuron 2001;30(1):135-47
   PubMed Web of Science ®Google Scholar
• Stevenson A, Yates DM, Manser C, Riluzole protects against glutamate-induced slowing of neurofilament axonal transport. Neurosci Lett 2009;454(2):161-4
   PubMed Web of Science ®Google Scholar
• Strong MJ, Volkening K, Hammond R, TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein. Mol Cell Neurosci 2007;35(2):320-7
   PubMed Web of Science ®Google Scholar
• Mitsumoto H, Tsuzaka K. Neurotrophic factors and neuro-muscular disease: II. GDNF, other neurotrophic factors, and future directions. Muscle Nerve 1999;22(8):1000-21
   PubMedGoogle Scholar
• Mitsumoto H, Tsuzaka K. Neurotrophic factors and neuromuscular disease: I. General comments, the neurotrophin family, and neuropoietic cytokines. Muscle Nerve 1999;22(8):983-99
   PubMed Web of Science ®Google Scholar
• ALS CNTF Treatment Study Group. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology 1996;46(5):1244-9
   PubMed Web of Science ®Google Scholar
• Miller RG, Petajan JH, Bryan WW, A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group. Ann Neurol 1996;39(2):256-60
   PubMed Web of Science ®Google Scholar
• The BDNF Study Group (Phase III). A controlled trial of recombinant methionyl human BDNF in ALS. Neurology 1999;52(7):1427-33
   PubMed Web of Science ®Google Scholar
• Lai EC, Felice KJ, Festoff BW, Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 1997;49(6):1621-30
   PubMed Web of Science ®Google Scholar
• Borasio GD, Robberecht W, Leigh PN, A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 1998;51(2):583-6
   PubMed Web of Science ®Google Scholar
• Sorenson EJ, Windbank AJ, Mandrekar JN, Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 2008;71(22):1770-5
   PubMed Web of Science ®Google Scholar
• Oosthuyse B, Moons L, Storkebaum E, Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 2001;28(2):131-8
   PubMed Web of Science ®Google Scholar
• Sathasivam S. VEGF and ALS. Neurosci Res 2008;62(2):71-7
   PubMed Web of Science ®Google Scholar
• Bogaert E, Van Damme P, Poesen K, VEGF protects motor neurons against excitotoxicity by upregulation of GluR2. Neurobiol Aging 2010;31(12):2185-91
   PubMed Web of Science ®Google Scholar
• Suzuki M, Watanabe T, Mikami H, Immunohistochemical studies of vascular endothelial growth factor in skin of patients with amyotrophic lateral sclerosis. J Neurol Sci 2009;285(1–2):125-9
   PubMed Web of Science ®Google Scholar
• Kern MA, Friese M, Grundstrom E, Amyotrophic lateral sclerosis: evidence for intact hepatocyte growth factor/met signalling axis. Cytokine 2001;15(6):315-19
   PubMed Web of Science ®Google Scholar
• Kato S, Funakoshi H, Nakamura T, Expression of hepatocyte growth factor and c-Met in the anterior horn cells of the spinal cord in the patients with amyotrophic lateral sclerosis (ALS): immunohistochemical studies on sporadic ALS and familial ALS with superoxide dismutase 1 gene mutation. Acta Neuropathol 2003;106(2):112-20
   PubMed Web of Science ®Google Scholar
• Sun W, Funakoshi H, Nakamura T. Overexpression of HGF retards disease progression and prolongs life span in a transgenic mouse model of ALS. J Neurosci 2002;22(15):6537-48
   PubMed Web of Science ®Google Scholar
• Kadoyama K, Funakoshi H, Ohya W, Nakamura T. Hepatocyte growth factor (HGF) attenuates gliosis and motoneuronal degeneration in the brainstem motor nuclei of a transgenic mouse model of ALS. Neurosci Res 2007;59(4):446-56
   PubMed Web of Science ®Google Scholar
• Ishigaki A, Aoki M, Nagai M, Intrathecal delivery of hepatocyte growth factor from amyotrophic lateral sclerosis onset suppresses disease progression in rat amyotrophic lateral sclerosis model. J Neuropathol Exp Neurol 2007;66(11):1037-44
   PubMed Web of Science ®Google Scholar
• Aoki M, Warita H, Suzuki N, Itoyama Y. Development of motor neuron restorative therapy in amyotrophic lateral sclerosis using hepatocyte growth factor. Rinsho Shinkeigaku 2009;49(11):814-17
   PubMedGoogle Scholar
• Penn RD, Kroin JS, York MM, Cedarbaum JM. Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial). Neurosurgery 1997;40(1):94-9; discussion 9-100
   PubMed Web of Science ®Google Scholar
• Aebischer P, Schluep M, Deglon N, Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat Med 1996;2(6):696-9
   PubMed Web of Science ®Google Scholar
• Guegan C, Przedborski S. Programmed cell death in amyotrophic lateral sclerosis. J Clin Invest 2003;111(2):153-61
   PubMed Web of Science ®Google Scholar
• Kostic V, Jackson-Lewis V, de Bilbao F, Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science 1997;277(5325):559-62
   PubMed Web of Science ®Google Scholar
• Gould TW, Buss RR, Vinsant S, Complete dissociation of motor neuron death from motor dysfunction by Bax deletion in a mouse model of ALS. J Neurosci 2006;26(34):8774-86
   PubMed Web of Science ®Google Scholar
• Pasinelli P, Houseweart MK, Brown RH Jr, Cleveland DW. Caspase-1 and -3 are sequentially activated in motor neuron death in Cu,Zn superoxide dismutase-mediated familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2000;97(25):13901-6
   PubMed Web of Science ®Google Scholar
• Li M, Ona VO, Guegan C, Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 2000;288(5464):335-9
   PubMed Web of Science ®Google Scholar
• Kieran D, Kalmar B, Dick JR, Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 2004;10(4):402-5
   PubMed Web of Science ®Google Scholar
• Kalmar B, Novoselov S, Gray A, Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS. J Neurochem 2008;107(2):339-50
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Shefner JM, Simpson E, Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis. Muscle Nerve 2008;38(1):837-44
   PubMed Web of Science ®Google Scholar
• Hall ED, Andrus PK, Oostveen JA, Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res 1996;742(1-2):80-8
   PubMed Web of Science ®Google Scholar
• Anderson DW, Neavin T, Smith JA, Schneider JS. Neuroprotective effects of pramipexole in young and aged MPTP-treated mice. Brain Res 2001;905(1-2):44-53
   PubMed Web of Science ®Google Scholar
• Cassarino DS, Fall CP, Smith TS, Bennett JP Jr. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J Neurochem 1998;71(1):295-301
   PubMed Web of Science ®Google Scholar
• Pattee GL, Post GR, Gerber RE, Bennett JP Jr. Reduction of oxidative stress in amyotrophic lateral sclerosis following pramipexole treatment. Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4(2):90-5
   PubMed Web of Science ®Google Scholar
• Abramova NA, Cassarino DS, Khan SM, Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma. J Neurosci Res 2002;67(4):494-500
   PubMed Web of Science ®Google Scholar
• Wang H, Larriviere KS, Keller KE, R+ pramipexole as a mitochondrially focused neuroprotectant: initial early phase studies in ALS. Amyotroph Lateral Scler 2008;9(1):50-8
   PubMed Web of Science ®Google Scholar
• Bozik MIE, Volles L, Mather J, KNS-760704-CL201, Part 1: A 12-week Phase 2 study of the safety, tolerability, and clinical effects of KNS 760704 in ALS subjects. Amyotroph Lateral Scler 2009;10(S1):28-9
   Google Scholar
• Cudkowicz MGD, Shefner J, Schoenfeld D, Ceftriaxone in ALS. Results of stages 1 and 2 of an adaptive design safety, pharmacokinetic and efficacy trial. Amyotroph Lateral Scler 2009;10:28-30
   Google Scholar
• Howes JF, Bell C. Talampanel. Neurotherapeutics 2007;4(1):126-9
   PubMed Web of Science ®Google Scholar
• Greene IP, Lee EY, Prow N, Protection from fatal viral encephalomyelitis: AMPA receptor antagonists have a direct effect on the inflammatory response to infection. Proc Natl Acad Sci USA 2008;105(9):3575-80
   PubMed Web of Science ®Google Scholar
• Denes L, Szilagyi G, Gal A, Nagy Z. Talampanel a non-competitive AMPA-antagonist attenuates caspase-3 dependent apoptosis in mouse brain after transient focal cerebral ischemia. Brain Res Bull 2006;70(3):260-2
   PubMed Web of Science ®Google Scholar
• Van Den Bosch L, Vandenberghe W, Klaassen H, Ca(2+)-permeable AMPA receptors and selective vulnerability of motor neurons. J Neurol Sci 2000;180(1-2):29-34
   PubMed Web of Science ®Google Scholar
• Pascuzzi RM, Shefner J, Chappell AS, A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010;11(3):266-71
   PubMed Web of Science ®Google Scholar
• Kiaei M, Petri S, Kipiani K, Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 2006;26(9):2467-73
   PubMed Web of Science ®Google Scholar
• Elliott JL. Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis. Brain Res Mol Brain Res 2001;95(1-2):172-8
   PubMedGoogle Scholar
• Hensley K, Floyd RA, Gordon B, Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. J Neurochem 2002;82(2):365-74
   PubMed Web of Science ®Google Scholar
• Poloni M, Facchetti D, Mai R, Circulating levels of tumour necrosis factor-alpha and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis. Neurosci Lett 2000;287(3):211-14
   PubMed Web of Science ®Google Scholar
• Neymotin A, Petri S, Calingasan NY, Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. Exp Neurol 2009;220(1):191-7
   PubMed Web of Science ®Google Scholar
• Stommel EW, Cohen JA, Fadul CE, Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial. Amyotroph Lateral Scler 2009;10(5-6):393-404
   PubMed Web of Science ®Google Scholar
• Meyer T, Maier A, Borisow N, Thalidomide causes sinus bradycardia in ALS. J Neurol 2008;255(4):587-91
   PubMed Web of Science ®Google Scholar
• Kiaei M. Peroxisome proliferator-activated receptor-gamma in amyotrophic lateral sclerosis and Huntington's disease. PPAR Res 2008;2008:418765
   PubMedGoogle Scholar
• Kiaei M, Kipiani K, Chen J, Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol 2005;191(2):331-6
   PubMed Web of Science ®Google Scholar
• Schutz B, Reimann J, Dumitrescu-Ozimek L, The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci 2005;25(34):7805-12
   PubMed Web of Science ®Google Scholar
• Shibata N, Kawaguchi-Niida M, Yamamoto T, Effects of the PPARgamma activator pioglitazone on p38 MAP kinase and IkappaBalpha in the spinal cord of a transgenic mouse model of amyotrophic lateral sclerosis. Neuropathology 2008;28(4):387-98
   PubMed Web of Science ®Google Scholar
• Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010;304(4):411-18
   PubMed Web of Science ®Google Scholar
• Storkebaum E, Lambrechts D, Dewerchin M, Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 2005;8(1):85-92
   PubMed Web of Science ®Google Scholar
• Azzouz M, Ralph GS, Storkebaum E, VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004;429(6990):413-17
   PubMed Web of Science ®Google Scholar
• Ito H, Wate R, Zhang J, Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol 2008;213(2):448-55
   PubMed Web of Science ®Google Scholar
• Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study). Amyotroph Lateral Scler 2006;7(4):241-5
   PubMed Web of Science ®Google Scholar
• Bordet T, Buisson B, Michaud M, Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther 2007;322(2):709-20
   PubMed Web of Science ®Google Scholar
• Waibel S, Reuter A, Malessa S, Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. J Neurol 2004;251(9):1080-4
   PubMed Web of Science ®Google Scholar
• Smith RA, Miller TM, Yamanaka K, Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 2006;116(8):2290-6
   PubMed Web of Science ®Google Scholar
• Wang R, Zhang D. Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model. Eur J Neurosci 2005;22(9):2376-80
   PubMed Web of Science ®Google Scholar
• Levine TD, Bowser R, Hank N, Saperstein D. A pilot trial of memantine and riluzole in ALS: correlation to CSF biomarkers. Amyotroph Lateral Scler2010;11(6):514-19
   PubMed Web of Science ®Google Scholar
• de Carvalho M, Pinto S, Costa J, A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010;11(5):456-60
   PubMed Web of Science ®Google Scholar
• Akaike A, Tamura Y, Sato Y, Yokota T. Protective effects of a vitamin B12 analog, methylcobalamin, against glutamate cytotoxicity in cultured cortical neurons. Eur J Pharmacol 1993;241(1):1-6
   PubMed Web of Science ®Google Scholar
• Kaji R, Kodama M, Imamura A, Effect of ultrahigh-dose methylcobalamin on compound muscle action potentials in amyotrophic lateral sclerosis: a double-blind controlled study. Muscle Nerve 1998;21(12):1775-8
   PubMed Web of Science ®Google Scholar
• Boatright JH, Nickerson JM, Moring AG, Pardue MT. Bile acids in treatment of ocular disease. J Ocul Biol Dis Inform 2009;2(3):149-59
   PubMedGoogle Scholar
• Ludolph AC, Bendotti C, Blaugrund E, Guidelines for preclinical animal research in ALS/MND: a consensus meeting. Amyotroph Lateral Scler 2010;11(1-2):38-45
   PubMed Web of Science ®Google Scholar
• Dimos JT, Rodolfa KT, Niakan KK, Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008;321(5893):1218-21
   PubMed Web of Science ®Google Scholar
• Gordon PH, Cheung YK, Levin B, A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotroph Lateral Scler 2008;9(4):212-22
   PubMed Web of Science ®Google Scholar